

Full-Life Technologies Announces Poster Presentation at AACR Annual Meeting 2026

Chengdu, China – April 8, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place in San Diego, USA from April 17 to 22, 2026. The Company will have a poster presentation.

Details of the poster are given in the table below:

Abstract Title	Detail Information
Discovery of FL-261 as a theranostic RDC vector for the treatment of c-MET overexpression cancers	<p>Session Title: Radiopharmaceutical Platforms for Theranostic Precision Oncology</p> <p>Session Start Time: 4/21/2026 2:00:00 PM</p> <p>Session End Time: 4/21/2026 5:00:00 PM</p> <p>Location: Poster Section 16</p> <p>Poster Board Number: 19</p> <p>Presentation Number: 5825</p>

About FL-261

FL-261 is a first-in-class vector for radioligand therapy treating c-MET overexpression cancers. In *in-vitro* assays, FL-261 shows tight binding affinity to c-MET protein with great selectivity. In tumor-bearing mice biodistribution models, radiolabeled FL-261 demonstrates high and c-MET-specific tumor uptake, with fast clearance from normal organs. Lastly, in the efficacy studies, [²²⁵Ac]Ac-FL-261 delivers promising anti-tumor activities in multiple xenograft models with low, medium and high levels of c-MET expression.

About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a fully integrated clinical-stage global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.

Media Contacts:

Full-Life

Email: pr@t-full.com

Website: www.full-life.com